Endomagnetics becomes Endomag as business expands into new markets
Thursday, 11 December, 2014
Endomagnetics is today revealing a new brand identity that accurately reflects its position as a global leader in the development of devices for cancer care based on the application of advanced magnetic technologies.
The identity for newly named Endomag has been built around the...
Endomagnetics receives IDE approval to initiate US trials
Monday, 1 December, 2014
Cancer healthcare company Endomagnetics announced today that it has received Investigational Device Exemption (IDE) approval from the United States Food and Drug Administration (FDA) to initiate a pivotal clinical trial to evaluate the safety and effectiveness of the SentiMag® and Sienna+®...
Endomagnetics Raises Further Funding for US Clinical Trial, Sales Support and New Product Development
Wednesday, 19 November, 2014
Endomagnetics, the Cambridge-based cancer healthcare company, has raised a further £2m ($3.12m US) to support its pivotal US clinical trial and the launch of a new cancer marker product in 2015.
The funds will also support market development beyond EMEA and Australasia, where the company...
SentiMag Now Available in Australia and New Zealand
Monday, 21 July, 2014
Endomagnetics is pleased to announce it has reached an agreement with Aurora BioScience as its exclusive distributor for Australia and New Zealand. This appointment significantly extends the availability of the company’s SentiMag® and Sienna+® tracer system. Breast cancer patients in the region...
Endomagnetics Completes Acquisition of the ACT Portfolio
Tuesday, 24 June, 2014
Endomagnetics, the company developing a portfolio of products to improve the standard of cancer care, announced today the acquisition of the ACT portfolio and related assets from Actium Biosystems, LLC. This move extends Endomagnetics’ oncology platform from diagnostics into therapeutics while...